The first guideline provides recommendations on the pharmacologic management of oligoarthritis, temporomandibular joint arthritis, and systemic JIA with or without macrophage activation syndrome.

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

By contrast, higher rates of uveitis in the German cohort were associated with biologic rather than methotrexate use, “perhaps explained because uveitis occurs most frequently in oligoarthritis patients, and those on [methotrexate] were not enrolled in BiKeR,” say Kearsley-Fleet and colleagues. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group Rheumatology 2021; doi:10.1093/rheumatology/keab641

3–9 November: Keep up with the latest news and interviews from the conference.

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.

Of these, 1280 had rheumatoid factor-negative polyarthritis and 761 had extended oligoarthritis.

The researchers analyzed data pertaining to 1957 children from 47 Italian hemato-oncology or rheumatology centers, including 1277 with cancer (64% hematologic and 36% solid malignancies) and 680 with JIA (65% oligoarthritis).

In all, 56% of study participants had oligoarthritis and the remaining 44% had polyarthritis.

How will the FAST trial results impact regulatory guidance & clinical practice?

Other factors significantly associated with achieving inactive disease and subsequent treatment discontinuation included younger age at start of treatment (HR=0.92), greater response to treatment within the first 6 months (HR=1.12), and persistent oligoarthritis (HR=1.89).

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.

The team used the DEPAR registry to evaluate the outcomes of PsA patients with oligoarthritis or polyarthritis who had data recorded between 2013 and 2018.

Similarly, the rates of involvement of more than one JADI-Extraarticular item were lower with biologic therapy than with methotrexate, at 16.2% versus 26.5% for patients with oligoarthritis and 13.5% versus 31.4% for those with polyarthritis.

She notes that clinical trial participants “tend to have polyarthritis,” and that registry studies of patients with oligoarthritis, enthesitis, and axial disease should be done.